ANI Pharmaceuticals, Inc. (BST:BSFA)

ANI Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	262.61	144.86	221.12	48.23	100.3	7.86
Short-Term Investments	8.86	6.31	-	-	-	-
Cash & Short-Term Investments	271.47	151.17	221.12	48.23	100.3	7.86
Cash Growth	77.11%	-31.64%	358.49%	-51.92%	1175.43%	-87.38%
Receivables	252.62	221.73	162.08	165.44	128.53	95.79
Inventory	146.48	136.78	111.2	105.36	81.69	60.8
Prepaid Expenses	18.35	17.78	17.4	8.39	7.59	5.86
Restricted Cash	0.04	0.03	-	5.01	-	-
Other Current Assets	9.45	0.2	8.02	11.85	3.67	-
Total Current Assets	698.4	527.68	519.82	344.26	321.78	170.32
Property, Plant & Equipment	63.56	56.86	44.59	43.25	52.67	41.27
Long-Term Investments	2.23	4.9	6.24	8.8	-	-
Goodwill	62.48	59.99	28.22	28.22	27.89	3.58
Other Intangible Assets	499.82	541.83	209.01	251.64	294.12	188.51
Long-Term Deferred Tax Assets	71.4	85.11	90.71	81.36	67.94	51.7
Long-Term Deferred Charges	0.7	0.9	-	-	-	-
Other Long-Term Assets	9.57	6.42	5.84	2.56	7.21	5.81
Total Assets	1,408	1,284	904.42	760.09	771.6	461.19
Accounts Payable	69.8	45.66	36.68	29.31	22.97	11.26
Accrued Expenses	135.45	90.76	57.84	35.89	27.89	22.92
Current Portion of Long-Term Debt	15.24	9.17	0.85	0.85	0.85	13.24
Current Portion of Leases	-	2.04	-	-	-	-
Current Income Taxes Payable	-	6.75	8.16	-	-	3.91
Current Unearned Revenue	-	-	-	-	-	0.08
Other Current Liabilities	50.07	39.3	41.94	33.4	35.83	27.16
Total Current Liabilities	270.56	193.68	145.48	99.44	87.54	78.57
Long-Term Debt	605.07	614.92	284.82	285.67	286.52	186.55
Long-Term Leases	11.27	4.55	-	1.38	-	-
Other Long-Term Liabilities	15.44	42.02	16.53	35.06	38.8	0.37
Total Liabilities	902.34	855.17	446.82	421.55	412.86	265.49
Common Stock	0	0	0	0	0	0
Additional Paid-In Capital	586.23	519.65	514.1	403.9	387.84	214.35
Retained Earnings	-50.59	-100.28	-80.13	-97.29	-47.77	-4.97
Treasury Stock	-32.64	-21.04	-10.08	-5.09	-3.14	-2.25
Comprehensive Income & Other	2.81	5.34	8.86	12.17	-3.06	-11.44
Total Common Equity	505.82	403.68	432.75	313.69	333.89	195.7
Shareholders' Equity	505.82	428.53	457.6	338.54	358.74	195.7
Total Liabilities & Equity	1,408	1,284	904.42	760.09	771.6	461.19
Total Debt	631.58	630.68	285.67	287.9	287.37	199.8
Net Cash (Debt)	-360.11	-479.51	-64.55	-239.67	-187.07	-191.93
Net Cash Per Share	-17.53	-24.82	-3.55	-14.74	-14.85	-16.04
Filing Date Shares Outstanding	20.9	20.31	19.72	16.35	16.55	12
Total Common Shares Outstanding	20.91	19.65	19.12	16.35	16.12	12
Working Capital	427.85	334	374.34	244.82	234.24	91.76
Book Value Per Share	24.19	20.54	22.64	19.18	20.71	16.31
Tangible Book Value	-56.48	-198.14	195.52	33.83	11.88	3.61
Tangible Book Value Per Share	-2.70	-10.08	10.23	2.07	0.74	0.30
Land	-	1.58	1.55	1.55	5.95	4.67
Buildings	-	24.44	17.88	16.66	19.97	11.63
Machinery	-	68.7	50.41	53.15	46.77	39.11
Construction In Progress	-	4.57	7.69	4.6	2.94	3.39
Leasehold Improvements	-	1.3	-	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.